Cure8 trial brief
This trial tests whether adding the oral antibiotic nifuroxazide to standard mesalamine improves quality of life for people with mild-to-moderate ulcerative colitis. Results, if published, could suggest a new adjunctive treatment option.
Adult patients with mild-to-moderate ulcerative colitis, gastroenterologists and IBD clinicians, and researchers interested in drug repurposing or antibiotic approaches for IBD.
This is a ClinicalTrials.gov record for a completed Phase 2/3 interventional study (NCT05988528) testing nifuroxazide added to standard mesalamine versus mesalamine alone in adults with mild-to-moderate ulcerative colitis.
The trial planned to enroll about 50 participants at Tanta University (Egypt) and treated patients for 6 months, with the primary outcome listed as change in IBDQ health-related quality of life. The intervention arms list mesalamine 1 g three times daily for all participants and the experimental arm adds nifuroxazide 200 mg twice daily.
Key eligibility limits included ages 18–60 and exclusion of severe UC, steroid or biologic/immunosuppressive use, and certain comorbidities. Registry status in the record is marked COMPLETED.
If you’re reading this because you or someone you care for has UC, this entry describes a registered clinical study of an oral antibiotic (nifuroxazide) given alongside mesalamine — it reports the study design and planned outcomes, not study results or treatment recommendations.
For questions about whether this approach is appropriate, talk with your treating clinician.
This entry is a trial registry record (Phase 2/3, listed as COMPLETED) and contains design and eligibility details rather than published trial results. Nifuroxazide is described here as an oral antibiotic; the record does not provide outcome data in this extract. Confirmed efficacy and safety would require peer-reviewed results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial tests whether an oral S1P modulator (etrasimod) is more effective than standard mesalazine for inducing remission in adults with active UC — a question that could affect initial treatment choices in China.
Many people with IBD have ongoing IBS-like symptoms despite little or no intestinal inflammation. This project targets brain–gut and autonomic mechanisms that might explain symptom persistence and tests a non-drug...
Early-phase trials test whether new treatments are safe and show biological activity. This study measures fecal calprotectin, a biomarker of intestinal inflammation, so it could provide early signals about whether ND-12...
